For example, VanMeter et al. [65] used RPPAs to quantitatively detect EGFR phosphorylations in samples from patients of non-small-cell lung cancer (NSCLC) carrying mutant EGFR compared with those carrying wild type EGFR, and revealed simultaneously-elevated phosphorylation at Tyr-1148 and Tyr-1068 and reduced phosphorylation at Tyr-1045 of EGFR. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.